[
    {
        "Gene name":"PROM1",
        "Genomic Position":"4:15969857-16085324(-) | 4p15.32",
        "CDS Mutation":null,
        "AA Mutation":"PROM1_EXPRESSION",
        "Disease":"Hepatocellular Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Resistance",
        "Therapies":"Sorafenib",
        "Description":"CD133 (PROM1) expression in 39 samples of hepatocellular carcinomas was correlated with JNK activity. Both were more highly expressed in patients not responding to sorafenib. CD133+ cells (sorted) were xenografted into mice, producing larger, more JNK inhibitor responsive tumors than CD133- xenografts.",
        "rs value":null,
        "pmid":"PubMed:22596232",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_Mutation",
        "Disease":"Hepatocellular Carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Refametinib,Sorafenib",
        "Description":"Phase 2 study in Asian patients with unresectable hepatocellular carcinoma. 70 patients received refametinib (BAY 86-9766) plus sorafenib as study treatment. A retrospective biomarker analysis was performed in 69 patients for KRAS, NRAS and BRAF mutations (BEAM technology). 4 patients were identified to harbor RAS mutations. 3 of whom still received study treatment at the cutoff date used for the final data analysis. These 3 patients had achieved confirmed PR, with duration responses ranging from 128 to 382 days. The fourth patient with a RAS mutation discontinued study treatment after 41 days on therapy due to PD. An overall of 4 (6 by modified RECIST) patients achieved PR.",
        "rs value":null,
        "pmid":"PubMed:25294897",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Refametinib + Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01915602",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KRAS",
        "Genomic Position":"12:25362365-25403737(-) | 12p12.1",
        "CDS Mutation":null,
        "AA Mutation":"KRAS_G12D",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":4,
        "Response to Drug":"Sensitivity",
        "Therapies":"Refametinib + Sorafenib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01915602",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGF19",
        "Genomic Position":"11:69513000-69519410(-) | 11q13.3",
        "CDS Mutation":null,
        "AA Mutation":"FGF19_Overexpression",
        "Disease":"Hepatocellular Carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Fisogatinib",
        "Description":"In a phase 1 trial, patients with hepatocellular carcinoma were treated with selective FGFR4 inhibitor, fisogatinib (BLU-554). For dose escalation, 25 patients received 140 to 900 mg fisogatinib once daily. FGF19 expression was evaluated by immunohistochemistry. Across doses, the overall response rate was 17% (11\/66) in FGF19 positive patients and 0% (0\/32) in FGF19 negative patients.",
        "rs value":null,
        "pmid":"PubMed:31575541",
        "source_db":"CIVIc"
    },
    {
        "Gene name":"BRCA1",
        "Genomic Position":"17:41197646-41277500(-) | 17q21.31",
        "CDS Mutation":null,
        "AA Mutation":"BRCA1_unspecified_or_BRCA2_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":0,
        "Response to Drug":"Sensitivity",
        "Therapies":"Temozolomide + Veliparib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01205828",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lapatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00107536",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB2",
        "Genomic Position":"17:37856333-37884915(+) | 17q12",
        "CDS Mutation":null,
        "AA Mutation":"ERBB2_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Varlitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03499626",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"AFP",
        "Genomic Position":"4:74301880-74321891(+) | 4q13.3",
        "CDS Mutation":null,
        "AA Mutation":"AFP_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Best supportive care + Ramucirumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02435433",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TERT",
        "Genomic Position":"5:1253282-1295162(-) | 5p15.33",
        "CDS Mutation":null,
        "AA Mutation":"TERT_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"RZ001",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05595473",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"EGFR",
        "Genomic Position":"7:55086794-55279321(+) | 7p11.2",
        "CDS Mutation":null,
        "AA Mutation":"EGFR_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Varlitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03499626",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB3",
        "Genomic Position":"12:56473645-56497289(+) | 12q13.2",
        "CDS Mutation":null,
        "AA Mutation":"ERBB3_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Varlitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03499626",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ERBB4",
        "Genomic Position":"2:212240446-213403565(-) | 2q34",
        "CDS Mutation":null,
        "AA Mutation":"ERBB4_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Varlitinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03499626",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V550L",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.C552F",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.?",
        "AA Mutation":"p.V550M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.1648G>C",
        "AA Mutation":"p.V550L",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.1648G>T",
        "AA Mutation":"p.V550L",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.1654T>C",
        "AA Mutation":"p.C552R",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"FGFR4",
        "Genomic Position":"5:176513887-176525145(+) | 5q35.2",
        "CDS Mutation":"c.1648G>A",
        "AA Mutation":"p.V550M",
        "Disease":"carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Resistance",
        "Therapies":"Fisogatinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:31575540",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"ALK",
        "Genomic Position":"2:29415640-30144432(-) | 2p23.2-p23.1",
        "CDS Mutation":null,
        "AA Mutation":"ALK_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ascrinvacumab",
        "Description":null,
        "rs value":null,
        "pmid":"Unindexed journals, Conference abstracts:NCT01911273",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ad5CMV-p53 gene",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT00003147",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"rAD-p53",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02509169",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"TP53",
        "Genomic Position":"17:7571720-7590856(-) | 17p13.1",
        "CDS Mutation":null,
        "AA Mutation":"TP53_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"rAD-p53",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02418988",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + MK-7684A",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05007106",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT03434379",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Atezolizumab + Bevacizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04102098",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Bevacizumab + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT04605796",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Camrelizumab + Lenvatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04443309",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04523493",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Tislelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04834986",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":1,
        "Response to Drug":"Sensitivity",
        "Therapies":"Lenvatinib + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT03841201",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04605731",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Apatinib + Camrelizumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04701060",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + TACE + Tremelimumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04522544",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Durvalumab + Tremelimumab + Yttrium-90 SIRT",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT04522544",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Icaritin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03236649",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Pembrolizumab",
        "Description":null,
        "rs value":null,
        "pmid":"FDA drug label:NCT02702414",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02576509",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"CD274",
        "Genomic Position":"9:5450525-5470547(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"CD274_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Thermal ablation + Toripalimab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05240404",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"NOTCH1",
        "Genomic Position":"9:139388896-139440314(-) | 9q34.3",
        "CDS Mutation":null,
        "AA Mutation":"NOTCH1_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Ginsenoside Rg3 capsule + Pirarubicin",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02724358",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"KIT",
        "Genomic Position":"4:55524085-55606881(+) | 4q12",
        "CDS Mutation":null,
        "AA Mutation":"KIT_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Sunitinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT00247676",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"JAK2",
        "Genomic Position":"9:4985245-5128183(+) | 9p24.1",
        "CDS Mutation":null,
        "AA Mutation":"JAK2_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"AZD1480",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01219543",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":2,
        "Response to Drug":"Sensitivity",
        "Therapies":"Cabozantinib + Nivolumab",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05039736",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tepotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01988493",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"c-Met\/PD-L1 CAR-T cells",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT03672305",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capmatinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT01964235",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"RC108",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT05628857",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tepotinib",
        "Description":null,
        "rs value":null,
        "pmid":"ClinicalTrials.gov:NCT02115373",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Capmatinib",
        "Description":null,
        "rs value":null,
        "pmid":"DOI:NCT01737827",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tivantinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT01755767",
        "source_db":"COSMIC"
    },
    {
        "Gene name":"MET",
        "Genomic Position":"7:116312459-116436396(+) | 7q31",
        "CDS Mutation":null,
        "AA Mutation":"MET_unspecified",
        "Disease":"liver | carcinoma | hepatocellular carcinoma",
        "therapy_rank":3,
        "Response to Drug":"Sensitivity",
        "Therapies":"Tivantinib",
        "Description":null,
        "rs value":null,
        "pmid":"PubMed:NCT02029157",
        "source_db":"COSMIC"
    }
]